Neuroendocrine Tumor Treatment Market 2027 by Types, Application, Technology, Opportunities, End Users and Regions | The Insight Partners

Neuroendocrine Tumor Treatment Market to 2027 - Global Analysis and Forecasts by Drugs ( Everolimus, Suininib Malate, Lu-Dotate, Lanreotide and Octreotide ); Indication ( Gastrointestinal NET, Lung NET, Pancreatic NET, and Others NET ); End User ( Hospitals, Oncology Centers and Others. )

Report Code: TIPRE00003843 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Neuroendocrine Tumor results from the abnormal growth of neoplasms that originate from cells of the various endocrine glands and nervous systems. These are generally infected first in intestine, which are often known as carcinoid tumors.

MARKET DYNAMICS
The Neuroendocrine Tumor Treatment Market is anticipated to grow in the forecast period owing to driving factors such as the growing incidence of GI and Lung Neuroendocrine tumors, rising demand for various imagining technique, dug portfolio expansion and development of new products.

MARKET SCOPE
The "Global Neuroendocrine Tumor Treatment Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Neuroendocrine Tumor Treatment market with detailed market segmentation by Drugs, Indication, End User and geography. The global Neuroendocrine Tumor Treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Neuroendocrine Tumor Treatment market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global Neuroendocrine Tumor Treatment market is segmented on the basis of Drugs, Indication and End User. Based on Drugs the market is segmented into Everolimus, Suininib Malate, Lu-Dotate, Lanreotide and Octreotide. Based on Indication the market is segmented into Gastrointestinal NET, Lung NET, Pancreatic NET, and Others NET. Based on End User the market is segmented into Hospitals, Oncology Centers and Others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Neuroendocrine Tumor Treatment market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Neuroendocrine Tumor Treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Neuroendocrine Tumor Treatment market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Neuroendocrine Tumor Treatment market in these regions.

MARKET PLAYERS
The reports cover key developments in the Neuroendocrine Tumor Treatment Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Neuroendocrine Tumor Treatment Market are anticipated to lucrative growth opportunities in the future with the rising demand for Neuroendocrine Tumor Treatment in the global market. Below mentioned is the list of few companies engaged in the Neuroendocrine Tumor Treatment market.

The report also includes the profiles of key Neuroendocrine Tumor Treatment market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Pfizer Inc
  • Novartis AG
  • Ipsen
  • Advanced Accelerator Applications
  • Tarveda Therapeutics
  • Progenics Pharmaceuticals,Inc
  • Hutchison Medipharma Limited
  • Dauntless Pharmaceuticals Inc
  • Exelixis
  • Mayo Clinic
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Neuroendocrine Tumor Treatment Market - By Drugs
1.3.2 Neuroendocrine Tumor Treatment Market - By Indication
1.3.3 Neuroendocrine Tumor Treatment Market - By End User
1.3.4 Neuroendocrine Tumor Treatment Market - By Region
1.3.4.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. NEUROENDOCRINE TUMOR TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. NEUROENDOCRINE TUMOR TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. NEUROENDOCRINE TUMOR TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. NEUROENDOCRINE TUMOR TREATMENT - GLOBAL MARKET OVERVIEW
6.2. NEUROENDOCRINE TUMOR TREATMENT - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. NEUROENDOCRINE TUMOR TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DRUGS
7.1. OVERVIEW
7.2. DRUGS MARKET FORECASTS AND ANALYSIS
7.3. EVEROLIMUS
7.3.1. Overview
7.3.2. Everolimus Market Forecast and Analysis
7.4. SUININIB MALATE
7.4.1. Overview
7.4.2. Suininib Malate Market Forecast and Analysis
7.5. LU-DOTATE
7.5.1. Overview
7.5.2. Lu-Dotate Market Forecast and Analysis
7.6. LANREOTIDE AND OCTREOTIDE
7.6.1. Overview
7.6.2. Lanreotide and Octreotide Market Forecast and Analysis
8. NEUROENDOCRINE TUMOR TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - INDICATION
8.1. OVERVIEW
8.2. INDICATION MARKET FORECASTS AND ANALYSIS
8.3. GASTROINTESTINAL NET
8.3.1. Overview
8.3.2. Gastrointestinal NET Market Forecast and Analysis
8.4. LUNG NET
8.4.1. Overview
8.4.2. Lung NET Market Forecast and Analysis
8.5. PANCREATIC NET
8.5.1. Overview
8.5.2. Pancreatic NET Market Forecast and Analysis
8.6. AND OTHERS NET
8.6.1. Overview
8.6.2. and Others NET Market Forecast and Analysis
9. NEUROENDOCRINE TUMOR TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. ONCOLOGY CENTERS AND OTHERS.
9.4.1. Overview
9.4.2. Oncology Centers and Others. Market Forecast and Analysis
10. NEUROENDOCRINE TUMOR TREATMENT MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Neuroendocrine Tumor Treatment Market Overview
10.1.2 North America Neuroendocrine Tumor Treatment Market Forecasts and Analysis
10.1.3 North America Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Drugs
10.1.4 North America Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Indication
10.1.5 North America Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By End User
10.1.6 North America Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Countries
10.1.6.1 United States Neuroendocrine Tumor Treatment Market
10.1.6.1.1 United States Neuroendocrine Tumor Treatment Market by Drugs
10.1.6.1.2 United States Neuroendocrine Tumor Treatment Market by Indication
10.1.6.1.3 United States Neuroendocrine Tumor Treatment Market by End User
10.1.6.2 Canada Neuroendocrine Tumor Treatment Market
10.1.6.2.1 Canada Neuroendocrine Tumor Treatment Market by Drugs
10.1.6.2.2 Canada Neuroendocrine Tumor Treatment Market by Indication
10.1.6.2.3 Canada Neuroendocrine Tumor Treatment Market by End User
10.1.6.3 Mexico Neuroendocrine Tumor Treatment Market
10.1.6.3.1 Mexico Neuroendocrine Tumor Treatment Market by Drugs
10.1.6.3.2 Mexico Neuroendocrine Tumor Treatment Market by Indication
10.1.6.3.3 Mexico Neuroendocrine Tumor Treatment Market by End User
10.1.6.4 US Neuroendocrine Tumor Treatment Market
10.1.6.4.1 US Neuroendocrine Tumor Treatment Market by Drugs
10.1.6.4.2 US Neuroendocrine Tumor Treatment Market by Indication
10.1.6.4.3 US Neuroendocrine Tumor Treatment Market by End User
10.2. EUROPE
10.2.1 Europe Neuroendocrine Tumor Treatment Market Overview
10.2.2 Europe Neuroendocrine Tumor Treatment Market Forecasts and Analysis
10.2.3 Europe Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Drugs
10.2.4 Europe Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Indication
10.2.5 Europe Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By End User
10.2.6 Europe Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Neuroendocrine Tumor Treatment Market
10.2.6.1.1 Germany Neuroendocrine Tumor Treatment Market by Drugs
10.2.6.1.2 Germany Neuroendocrine Tumor Treatment Market by Indication
10.2.6.1.3 Germany Neuroendocrine Tumor Treatment Market by End User
10.2.6.2 France Neuroendocrine Tumor Treatment Market
10.2.6.2.1 France Neuroendocrine Tumor Treatment Market by Drugs
10.2.6.2.2 France Neuroendocrine Tumor Treatment Market by Indication
10.2.6.2.3 France Neuroendocrine Tumor Treatment Market by End User
10.2.6.3 Italy Neuroendocrine Tumor Treatment Market
10.2.6.3.1 Italy Neuroendocrine Tumor Treatment Market by Drugs
10.2.6.3.2 Italy Neuroendocrine Tumor Treatment Market by Indication
10.2.6.3.3 Italy Neuroendocrine Tumor Treatment Market by End User
10.2.6.4 Spain Neuroendocrine Tumor Treatment Market
10.2.6.4.1 Spain Neuroendocrine Tumor Treatment Market by Drugs
10.2.6.4.2 Spain Neuroendocrine Tumor Treatment Market by Indication
10.2.6.4.3 Spain Neuroendocrine Tumor Treatment Market by End User
10.2.6.5 United Kingdom Neuroendocrine Tumor Treatment Market
10.2.6.5.1 United Kingdom Neuroendocrine Tumor Treatment Market by Drugs
10.2.6.5.2 United Kingdom Neuroendocrine Tumor Treatment Market by Indication
10.2.6.5.3 United Kingdom Neuroendocrine Tumor Treatment Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Neuroendocrine Tumor Treatment Market Overview
10.3.2 Asia-Pacific Neuroendocrine Tumor Treatment Market Forecasts and Analysis
10.3.3 Asia-Pacific Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Drugs
10.3.4 Asia-Pacific Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Indication
10.3.5 Asia-Pacific Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Neuroendocrine Tumor Treatment Market
10.3.6.1.1 Australia Neuroendocrine Tumor Treatment Market by Drugs
10.3.6.1.2 Australia Neuroendocrine Tumor Treatment Market by Indication
10.3.6.1.3 Australia Neuroendocrine Tumor Treatment Market by End User
10.3.6.2 China Neuroendocrine Tumor Treatment Market
10.3.6.2.1 China Neuroendocrine Tumor Treatment Market by Drugs
10.3.6.2.2 China Neuroendocrine Tumor Treatment Market by Indication
10.3.6.2.3 China Neuroendocrine Tumor Treatment Market by End User
10.3.6.3 India Neuroendocrine Tumor Treatment Market
10.3.6.3.1 India Neuroendocrine Tumor Treatment Market by Drugs
10.3.6.3.2 India Neuroendocrine Tumor Treatment Market by Indication
10.3.6.3.3 India Neuroendocrine Tumor Treatment Market by End User
10.3.6.4 Japan Neuroendocrine Tumor Treatment Market
10.3.6.4.1 Japan Neuroendocrine Tumor Treatment Market by Drugs
10.3.6.4.2 Japan Neuroendocrine Tumor Treatment Market by Indication
10.3.6.4.3 Japan Neuroendocrine Tumor Treatment Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Neuroendocrine Tumor Treatment Market Overview
10.4.2 Middle East and Africa Neuroendocrine Tumor Treatment Market Forecasts and Analysis
10.4.3 Middle East and Africa Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Drugs
10.4.4 Middle East and Africa Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Indication
10.4.5 Middle East and Africa Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Neuroendocrine Tumor Treatment Market
10.4.6.1.1 South Africa Neuroendocrine Tumor Treatment Market by Drugs
10.4.6.1.2 South Africa Neuroendocrine Tumor Treatment Market by Indication
10.4.6.1.3 South Africa Neuroendocrine Tumor Treatment Market by End User
10.4.6.2 Saudi Arabia Neuroendocrine Tumor Treatment Market
10.4.6.2.1 Saudi Arabia Neuroendocrine Tumor Treatment Market by Drugs
10.4.6.2.2 Saudi Arabia Neuroendocrine Tumor Treatment Market by Indication
10.4.6.2.3 Saudi Arabia Neuroendocrine Tumor Treatment Market by End User
10.4.6.3 U.A.E Neuroendocrine Tumor Treatment Market
10.4.6.3.1 U.A.E Neuroendocrine Tumor Treatment Market by Drugs
10.4.6.3.2 U.A.E Neuroendocrine Tumor Treatment Market by Indication
10.4.6.3.3 U.A.E Neuroendocrine Tumor Treatment Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Neuroendocrine Tumor Treatment Market Overview
10.5.2 South and Central America Neuroendocrine Tumor Treatment Market Forecasts and Analysis
10.5.3 South and Central America Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Drugs
10.5.4 South and Central America Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Indication
10.5.5 South and Central America Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By End User
10.5.6 South and Central America Neuroendocrine Tumor Treatment Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Neuroendocrine Tumor Treatment Market
10.5.6.1.1 Brazil Neuroendocrine Tumor Treatment Market by Drugs
10.5.6.1.2 Brazil Neuroendocrine Tumor Treatment Market by Indication
10.5.6.1.3 Brazil Neuroendocrine Tumor Treatment Market by End User
10.5.6.2 Argentina Neuroendocrine Tumor Treatment Market
10.5.6.2.1 Argentina Neuroendocrine Tumor Treatment Market by Drugs
10.5.6.2.2 Argentina Neuroendocrine Tumor Treatment Market by Indication
10.5.6.2.3 Argentina Neuroendocrine Tumor Treatment Market by End User
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. NEUROENDOCRINE TUMOR TREATMENT MARKET, KEY COMPANY PROFILES
12.1. PFIZER INC
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. NOVARTIS AG
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. IPSEN
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. ADVANCED ACCELERATOR APPLICATIONS
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. TARVEDA THERAPEUTICS
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. PROGENICS PHARMACEUTICALS,INC
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. HUTCHISON MEDIPHARMA LIMITED
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. DAUNTLESS PHARMACEUTICALS INC
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. EXELIXIS
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. MAYO CLINIC
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

- Pfizer Inc
- Novartis AG
- Ipsen
- Advanced Accelerator Applications
- Tarveda Therapeutics
- Progenics Pharmaceuticals,Inc
- Hutchison Medipharma Limited
- Dauntless Pharmaceuticals Inc
- Exelixis
- Mayo Clinic
Select License Type
USD $3000
USD $4550
USD $6550
USD $8550

Free

20%

customization on Pre-Booking
Pre Book